Tempus AI, Inc is a healthcare technology company. The company is headquartered in Chicago, Illinois.
| Revenue (TTM) | $1.36B |
| Gross Profit (TTM) | $864.74M |
| EBITDA | $-185.25M |
| Operating Margin | -24.30% |
| Return on Equity | -81.60% |
| Return on Assets | -9.07% |
| Revenue/Share (TTM) | $7.74 |
| Book Value | $2.32 |
| Price-to-Book | 18.55 |
| Price-to-Sales (TTM) | 5.66 |
| EV/Revenue | 6.16 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 36.10% |
| Shares Outstanding | $175.02M |
| Float | $114.45M |
| % Insiders | 36.98% |
| % Institutions | 54.73% |
Volatility is currently contracting
TEM heads into Q2 earnings with 21.3% expected revenue growth, strong diagnostics demand and AI deals, but near-term margin pressure remains.
Tempus (TEM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of its OneOme pharmacogenomics (PGx) testing solution, delivering advanced genetic insights to optimize medication safety, dosing and toxicity risk assessment. Following its acquisition of OneOme in November 2025, Tempus has fully integrated these capabilities to expand its comprehensive precision medicine po.
Tempus AI NASDAQ: TEM executives said the company's planned acquisition of Personalis is intended to strengthen its position in minimal residual disease, or MRD, testing, while expanding its biopharma data and profiling capabilities.
NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- Julie & Holleman LLP, a nationally recognized shareholder rights firm, is investigating the proposed acquisition of Personalis, Inc. (Nasdaq: PSNL) by Tempus AI, Inc. (Nasdaq: TEM), an existing Personalis shareholder and strategic partner.
Tempus AI (NASDAQ:TEM) will acquire Personalis (NASDAQ:PNSL) in a stock deal valued at $1.5 billion, expanding its reach in the market for tests that monitor cancer recurrence after treatment. Personalis shareholders will receive $16.25 per share, a 6% premium to Friday's closing price and a 28% premium to the unaffected 30-day volume-weighted average price.
Tempus AI, a healthcare tech company, is a favorite of investor Cathie Wood. Personalis does cancer testing.
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that it has entered into a definitive agreement to acquire Personalis, Inc. (NASDAQ: PSNL). The acquisition will expand Tempus' capabilities in minimal residual disease (MRD) and enhance its ability to support patients from diagnosis and treatment selection, to recurrence and monitoring. Under the terms of the agreement, Persona.
Tempus AI, Inc. earns a Strong Buy rating due to its transformation into a healthcare data giant with high-margin, rapidly growing data services. TEM's Q1 2026 data segment revenue surged 40% YoY to $87M, with robust bookings and visibility, positioning the segment for $500M+ revenue in 2026. MRD testing volume rose 500% YoY, driven by a highly sensitive, reimbursed test partnership with Personalis, fueling valuable data acquisition for pharma clients.
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it will report financial results for the second quarter ended June 30, 2026, on Thursday, July 30, 2026. The company will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the results and provide a business update. The call will be led by Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on TEM and any ticker you trade — then tracks every position and per-strategy win rate.
